Proliferation Of Ocular Disorders To Drive The Dry Eye Syndrome Treatment Market

With an unimaginable increase in eye disorders, Persistence Market Research has walked through the inevitable pointers of the dry eye syndrome treatment market.

Eye Syndrome Treatment Market: Criticalities and Dynamics

The global dry eye syndrome treatment market, by product, spans cyclosporine, topical corticosteroids, artificial tears, punctal plugs (removable and dissolvable), omega supplements, and likewise. Prescription-wise, it’s OTC, Rx and medical devices. BY distribution channel, it’s eye health clinics, hospital pharmacies, online pharmacies, and retail pharmacies.

Out of these, artificial tears hold more than 60% of the market share due to simple usage and higher efficacy on the part of artificial tears. Otherwise, prescription drugs dominate in comparison with OTC drugs. This could be credited to growing number of ocular care centers.

Additionally, prevalence of dry eye Meibomian gland dysfunction is asking for dry eye syndrome treatment. Various supply chain activities are being developed by retail Bio- pharmacies, which renders them as a leading distribution channel for dry eye syndrome treatment market.

How about Analysis Region-wise?

North America holds the largest market share due to the ever-growing adoption rate of dry eye syndrome treatment by the US. Europe stands second with the UK increasingly asking for LASIK procedures. Coming to the Asia-Pacific, huge target population followed by cheap labor is expected to take it to a greater stride in the dry eye syndrome treatment market in the near future. MEA is yet to catch up in this regard due to comparatively less expenditure on healthcare.

The Competitors are into the following….

The key participants in the dry eye syndrome treatment market are inclusive of Novartis AG, Allergan plc, Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Bausch Health Companies Inc., Akorn, Inc., Johnson & Johnson, Inc., Thea Pharmaceuticals Ltd., OASIS Medical, Altaire Pharmaceuticals Inc., Boiron USA, Similasan Corporation, Scope Ophthalmics Ltd., Reckitt Benckiser Group plc, Medicom Healthcare Ltd., FDC Ltd., Lupin Limited, Jamjoom Pharmaceuticals Co., Sentiss Pharma Private Ltd.

Coming to developments, Sun Pharmaceutical Industries Ltd., in October 2019, did announce launching CEQUA to treat dry eye syndrome all over the US. CEQUA is abreast with cyclosporine and has been approved by the US FDA for ophthalmic use. Novartis, in July 2019, did announce acquisition of Xiidra 5% (the sole prescription treatment approved for treating signs as well as symptoms of dry eye syndrome by exercising control over inflammation caused due to disease.

Along with these details, Persistence Market Research has made sure to delve deep into dry eye syndrome treatment market in insights, so as to give an eagle eyeview to the key players.